trending Market Intelligence /marketintelligence/en/news-insights/trending/ibTVXYlKrW-cUVAr6wH9mw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA clears CytomX's investigational new drug application for cancer drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA clears CytomX's investigational new drug application for cancer drug

The U.S. FDA cleared CytomX Therapeutics Inc.'s investigational new drug application for its lead program CX-072 for the treatment of cancer.

CytomX plans to immediately initiate a clinical study and open clinical sites to support patient enrollment.

The clinical study will include phase 1/2 trials evaluating CX-072 as monotherapy and in combination with Yervoy or Zelboraf in patients with metastatic or locally advanced unresectable solid tumors or lymphomas.

Clinical data from the study is expected in late 2017 and throughout 2018.